ELI LILLY & Co LLY 70.47
Health Care · NYSE · Data as of 2026-10-29
ELI LILLY & Co (LLY) has delivered +12.2% annualized revenue growth, n/a earnings growth, and +11.3% dividend growth over 10 years of data. Ranked #250 of 1968 stocks overall and #25 of 260 in the Health Care sector by Steady Score.
About ELI LILLY & Co
Company Overview
Eli Lilly develops and sells prescription medicines for diabetes, obesity, cancer, immunology and neuroscience conditions. Its products include injectable and oral therapies used by patients under medical supervision, with newer incretin medicines serving diabetes and chronic weight management. Physicians, hospitals and pharmacies deliver the medicines, while insurers and government programs determine much of patient access and reimbursement worldwide.
Read more
Business Model & Revenue
Revenue comes from patented medicines sold through wholesalers and healthcare channels. Prescription volume, approved uses, supply capacity, pricing and payer coverage drive sales. Patent protection is temporary, so Lilly invests heavily in discovery, clinical trials and manufacturing and also licenses external science. Successful products fund a pipeline with high failure risk, while rebates and government pricing reduce realized revenue.
Key Facts & Market Position
Lilly has major positions in metabolic disease through Mounjaro and Zepbound, creating strong demand and substantial manufacturing requirements. The portfolio also includes oncology, immunology and neuroscience medicines, reducing but not removing product concentration. Clinical evidence, regulator decisions, injection-device supply and global production expansion are central to translating demand into treated patients.